What's Happening?
Sidley Austin has strengthened its life sciences transactions practice by appointing Jiqiang Lin as a partner in its New York office. Lin joins Sidley Austin after a four-year tenure at Cooley, where he was recently promoted to senior counsel. His expertise
lies in intellectual property-focused commercial deals, particularly in biotechnology and pharmaceutical sectors. Lin's arrival is part of Sidley Austin's strategic expansion of its transactional life sciences practice on the East Coast, complementing recent growth in Boston and New York. Lin's background includes roles at Latham & Watkins and Pfizer, and his experience spans licensing, collaboration, and partnering transactions in advanced therapeutic areas.
Why It's Important?
The appointment of Jiqiang Lin is significant for Sidley Austin as it enhances the firm's capabilities in advising on complex transactions involving cutting-edge technologies in the life sciences sector. This move is expected to bolster Sidley Austin's position in the competitive legal market, particularly in the East Coast's burgeoning life sciences industry. Lin's expertise in high-stakes matters will likely attract more clients seeking counsel on innovative therapeutic platforms, thereby expanding Sidley Austin's client base and influence in the sector.
